GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oncorus Inc (OTCPK:ONCR) » Definitions » Interest Coverage

Oncorus (Oncorus) Interest Coverage : 0 (At Loss) (As of Mar. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Oncorus Interest Coverage?

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income by its Interest Expense. Oncorus's Operating Income for the three months ended in Mar. 2023 was $-15.13 Mil. Oncorus's Interest Expense for the three months ended in Mar. 2023 was $-1.20 Mil. did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is.

The historical rank and industry rank for Oncorus's Interest Coverage or its related term are showing as below:


ONCR's Interest Coverage is not ranked *
in the Biotechnology industry.
Industry Median: 138.73
* Ranked among companies with meaningful Interest Coverage only.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.


Oncorus Interest Coverage Historical Data

The historical data trend for Oncorus's Interest Coverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Oncorus Interest Coverage Chart

Oncorus Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22
Interest Coverage
No Debt No Debt N/A N/A -

Oncorus Quarterly Data
Dec18 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
Interest Coverage Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only N/A - - - -

Competitive Comparison of Oncorus's Interest Coverage

For the Biotechnology subindustry, Oncorus's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Oncorus's Interest Coverage Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oncorus's Interest Coverage distribution charts can be found below:

* The bar in red indicates where Oncorus's Interest Coverage falls into.



Oncorus Interest Coverage Calculation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

If Interest Expense is negative and Operating Income is positive, then

Interest Coverage=-1* Operating Income /Interest Expense

Else if Interest Expense is negative and Operating Income is negative, then

The company did not have earnings to cover the interest expense.

Else if Interest Expense is 0 and Long-Term Debt & Capital Lease Obligation is 0, then

The company had no debt (1).


Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Oncorus's Interest Coverage for the fiscal year that ended in Dec. 2022 is calculated as

Here, for the fiscal year that ended in Dec. 2022, Oncorus's Interest Expense was $-2.01 Mil. Its Operating Income was $-76.54 Mil. And its Long-Term Debt & Capital Lease Obligation was $47.85 Mil.

Oncorus did not have earnings to cover the interest expense.

Oncorus's Interest Coverage for the quarter that ended in Mar. 2023 is calculated as

Here, for the three months ended in Mar. 2023, Oncorus's Interest Expense was $-1.20 Mil. Its Operating Income was $-15.13 Mil. And its Long-Term Debt & Capital Lease Obligation was $47.52 Mil.

Oncorus did not have earnings to cover the interest expense.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's Financial Strength is.


Oncorus  (OTCPK:ONCR) Interest Coverage Explanation

Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.

Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .


Oncorus Interest Coverage Related Terms

Thank you for viewing the detailed overview of Oncorus's Interest Coverage provided by GuruFocus.com. Please click on the following links to see related term pages.


Oncorus (Oncorus) Business Description

Traded in Other Exchanges
N/A
Address
4 Corporate Drive, Andover, MA, USA, 01810
Oncorus Inc is a preclinical-stage biopharmaceutical company focused on the intravenous administration of self-amplifying RNA to transform outcomes for cancer patients. The company is in the process of developing intratumorally and intravenously administered product candidates designed to selectively attack and kill tumor cells and stimulate multiple arms of the immune system against tumors. Its pipeline product includes ONCR-021 and ONCR-788 which are based on coxsackievirus A21 or CVA21, and Seneca Valley Virus, or SVV, respectively.
Executives
Brian J. Shea officer: Interim CEO C/O ONCORUS, INC., 4 CORPORATE DRIVE, ANDOVER MA 01810
Alexander Nolte officer: Interim CFO 35 GATEHOUSE DRIVE, BUILDING D, FLOOR 3, WALTHAM MA 02451
James E Flynn director, 10 percent owner, other: *Possible Member of 10% Group 780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017
Douglas Fambrough director C/O DICERNA PHARMACEUTICALS, INC., 75 HAYDEN AVENUE, LEXINGTON MA 02421
Rick Wanstall officer: CFO and Treasurer C/O AILERON THERAPEUTICS, INC., 490 ARSENAL WAY, WATERTOWN MA 02472
Stephen Harbin officer: COO and Chief of Staff C/O ONCORUS, INC., 50 HAMPSHIRE STREET, SUITE 401, CAMBRIDGE MA 02139
Barbara Yanni director 1018 W. 8TH AVENUE, SUITE A, KING OF PRUSSIA PA 19406
Eric Rubin director C/O ONCORUS, INC., 50 HAMPSHIRE STREET, SUITE 401, CAMBRIDGE MA 02139
Christophe Queva officer: CSO and SVP, Research C/O ONCORUS, INC., 50 HAMPSHIRE STREET, SUITE 401, CAMBRIDGE MA 02139
Scott A Canute director FLEXION THERAPEUTICS, INC., 10 MALL ROAD, SUITE 301, BURLINGTON MA 01803
Mpm Bioventures 2014, L.p. 10 percent owner C/O MPM ASSET MANAGEMENT LLC, 450 KENDALL STREET, CAMBRIDGE MA 02142
Luke Evnin director, 10 percent owner THE JOHN HANCOCK TOWER, 200 CLARENDON STREET, 54TH STREET, BOSTON MA 02116
Oncology Impact Fund (cayman) Management L.p. 10 percent owner 450 KENDALL STREET, CAMBRIDGE MA 02142
Mpm Asset Management Investors Sunstates Fund Llc 10 percent owner 450 KENDALL STREET, CAMBRIDGE MA 02142
Ansbert Gadicke 10 percent owner THE JOHN HANCOCK TOWER, 200 CLARENDON STREET, 54TH FLOOR, BOSTON MA 02116

Oncorus (Oncorus) Headlines

From GuruFocus

Oncorus to Present at the Jefferies Global Healthcare Conference

By GuruFocusNews GuruFocusNews 06-11-2022

Oncorus to Present at the H.C. Wainwright Global Investment Conference

By GuruFocusNews GuruFocusNews 05-27-2022

Oncorus to Present at the Jefferies Global Healthcare Conference

By GuruFocusNews GuruFocusNews 07-01-2022

Oncorus to Present at the H.C. Wainwright Global Investment Conference

By GuruFocusNews GuruFocusNews 06-06-2022